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CeramideOur previous studies have shown that camptothecin and doxorubicin triggered ceramide accumulation via de
novo synthesis pathway. Denovo ceramide generationwas responsible for the drug-induced apoptosis through a
caspase-3-dependent pathway and a decrease of thrombospondin-1 expression in human thyroid carcinoma
FTC-133 cells. Here, we demonstrate that Jun N-terminal kinases play a critical role in camptothecin- and
doxorubicin-induced down-regulation of thrombospondin-1 expression: i) de novo ceramide synthesis pathway
activates Jun N-terminal kinase 1/2 resulting in activating transcription factor 2 phosphorylation; ii) cell
treatment bySP600125, a JunN-terminal kinase speciﬁc inhibitor, strongly reduced activating transcription factor
2 phosphorylation and completely abolished camptothecin and doxorubicin effects; and iii) activating
transcription factor 2 expression silencing greatly attenuated camptothecin- and doxorubicin-induced down-
regulation of thrombospondin-1 expression and apoptosis. The set of our data established that camptothecin- and
doxorubicin-induced activation of Jun N-terminal kinase/activating transcription factor 2 pathway via de novo
ceramide synthesis down-regulates thrombospondin-1 expression and apoptosis in human thyroid carcinoma
FTC-133 cells.RS 6237, UFR Sciences, BP 1039,
33 326918366.
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Thrombospondin-1 (TSP-1) is a 450 kDa multifunctional regulatory
glycoprotein involved in cell proliferation, apoptosis, angiogenesis, cell
adhesion and motility [1]. The α-granules of platelets have been
regarded as themain source of TSP-1 yet endothelial cells,macrophages,
ﬁbroblasts, and smoothmuscle cells can also produce TSP-1 [2]. Several
studies have highlighted the TSP-1 interactions with the extracellular
matrix and miscellaneous cell surface molecules including integrin,
CD36 [3], CD47, low density lipoprotein (LDL) receptor related protein
and proteoglycans [4]. It is now widely accepted that the biological
effects of TSP-1 differ according to the cell type and the pattern of
membrane receptors expressed by the target cells.
We have previously reported that camptothecin (CPT) and
doxorubicin (DOX), inhibitors of topoisomerase I and II, respectively,
were able to inhibit TSP-1 expression and thereby were able to induce
apoptosis in human thyroid carcinoma FTC-133 cells. Furthermore,
CPT- and DOX-induced apoptosis was signiﬁcantly decreased in the
presence of CD47/IAP-binding peptide 4N1, a peptide derived from
the C-terminal domain of TSP-1 [5]. These ﬁndings suggest that
induction of apoptosis by CPT and DOX in FTC-133 cells is dependenton the down-regulation of TSP-1 expression shedding light on a
potential role for TSP-1 in cell response to chemotherapy. Moreover,
we have reported that both CPT- and DOX-triggered ceramide
production in FTC-133 cells by activating the de novo synthesis
pathway. Importantly, ceramide could mediate both CPT- and DOX-
induced apoptosis and TSP-1-decreased expression [6].
A wealth of reports have suggested that kinases such as ERK 1/2,
JNK 1/2 and p38 kinases represent one of the key steps in signaling
cascades initiated by the binding of survival factor or activation of
death receptors that control the survival/apoptosis balance [7–9].
Activation of JNK has been proposed as a potential mechanism leading
to cell death during development or pathophysiological condi-
tions [10]. On one hand, ceramide has been reported to mediate cell
death through activation of JNK [11–13]. On the other hand, JNK has
been suggested to play a role in response to chemotherapeutic agents
via the activating transcription factor 2 (ATF-2) [14]. Recent ﬁndings
also suggest that the JNK pathway can regulate TSP-1 expression [15].
Despite that, the relationship between the JNK/ATF-2 signaling
pathway and TSP-1 expression remains an unresolved question in
cancer.
Herein, we demonstrate that CPT and DOX can activate JNK in FTC-
133 cells in a de novo ceramide synthesis pathway, which thereby
induce ATF-2 phosphorylation. Accordingly, treatment with the JNK
inhibitor SP600125 or siRNA strategy against ATF-2 could restore TSP-
1 expression and abrogate apoptosis in response to CPT and DOX.
Collectively, our results suggest that the JNK/ATF-2 signaling pathway
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1 and apoptosis in FTC-133 cell.2. Experimental procedures
2.1. Cells and materials
FTC-133 is a human follicular thyroid carcinoma derived cell line
(ECACC94060901) obtained from a lymph node metastasis of a single
patient [16]. Doxorubicin was from Farmitalia (Milano, Italy),
Dulbecco's modiﬁed Eagle's medium/F-12 and trypsin were from
Invitrogen (Cergy Pontoise, France). Bovine fetal serum was from
Dutscher (Brumath, France). Monoclonal TSP-1 antibody was from
Labvision. Mouse monoclonal antibody raised against recombinant
human pATF-2 was from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA). Monoclonal ATF-2, pATF-2 and procaspase-3 antibodies were
from Cell Signaling Technology. β-actin antibody was from Sigma.
ATF-2 siRNA Kit was from Santa Cruz Biotechnology Inc. ECL Western
blotting detection reagents were from Amersham (Freibourg,
Germany). Fumonisin B1 (FB1) was purchased from ALEXIS Corpo-
ration (Lausen, Switzerland). All other reagents were from Sigma (St.
Louis, MO, USA).Fig. 1. Effect of CPT, DOX and C2-ceramide on JNK phosphorylation. A, FTC-133 cells were in
The cell lysates containing equal amounts of total proteins were resolved by SDS–PAGE and
treated for 12 hours by either 5 μM CPT or 5 μMDOXwith or without the ceramide synthase
the Experimental procedures section. β-actin antibody was used as a control. The intensity2.2. FTC-133 cell culture conditions
Cells were routinely grown in Dulbecco's modiﬁed Eagle's
medium/F-12 (1:1) supplemented with 10% (vol./vol.) heat inacti-
vated fetal calf serum, 100 μg/mL streptomycin and 100 IU/mL
penicillin. Cells were cultured in 75 cm2 ﬂasks at 37 °C in a 5% CO2/
95% air–water saturated atmosphere as previously described [5].
Trypsinization was performed at conﬂuence. Cells were then cultured
in 96-well plates for cell viability assay and in 6-well culture plates for
Western blot analysis, mRNA extraction and caspase assay during the
exponential phase of cell growth.2.3. Western blotting
The cells were maintained in serum free culture medium for
24 hours before treatment. Conditioned media were collected and
centrifuged (3000g, 5 min, 4 °C). Cells were then washed with ice-
cold PBS, lysed in ice cold buffer containing 10 mM Tris pH 7.4,
150 mMNaCl, 5 mM EDTA, 1 mMNa3VO4, 1 mM dithiothreitol, 10 μg/
mL leupeptin, 10 μg/mL aprotinin, 10% (vol./vol.) glycerol, 1% Brij
(vol./vol.), placed on ice for 20 min and then centrifuged (14000g,
15 min, 4 °C to prepare whole cell extracts). Nuclear extracts werecubated with either 5 μM CPT, 5 μM DOX or 20 μM C2-ceramide for the indicated times.
analyzed by Western blot using anti-pJNK and anti-JNK antibody. B, FTC-133 cells were
inhibitor (FB1). Detection of pJNK or JNK was evaluated byWestern-blot as described in
of the bands was quantiﬁed by densitometry using quantity one program.
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Fig. 2. Effect of CPT, DOX and C2-ceramide on cell viability. A, FTC-133 cells were
incubated with either 5 μM CPT or 5 μM DOX in the absence or presence of 20 nM
SP600125 for the indicated times. Cell viability was determined by Upti-blue assay as
described in Experimental procedures. B, FTC-133 cells were incubated for 24 hours
with 20 μM C2-ceramide in the absence or presence of 20 nM SP600125. Cell viability
was determined by Upti-blue assay as described in Experimental procedures. Results
are expressed as percent of control and represent means±standard deviations (S.D.) of
at least three independent experiments.
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pended in 20 mM HEPES, 25% (vol./vol.) glycerol, 0.5 M NaCl, 1.5 mM
MgCl2, 0.5 mM EDTA. Protease inhibitor cocktails (Sigma) were added
to each buffer. The amount of proteins was determined using the BCA
protein quantiﬁcation kit (Interchim, Montluçon, France). Equal
amounts of proteins (whole cell extracts and nuclear extracts) were
resolved by 10% SDS–PAGE gels and transferred to nitrocellulose
sheets and probed with the appropriate antibodies (monoclonal anti-
TSP-1: dilution 1/400, polyclonal anti-PARP: dilution 1/1000, mono-
clonal anti-pATF-2: 1/1000 or anti-β-actin: dilution 1/8000). Horse-
radish peroxidase-conjugated goat anti-rabbit or anti-mouse IgG
were used as secondary antibodies (dilution 1/4000 and 1/10000,
respectively) and proteins were detected using an enhanced
chemiluminescence (ECL) kit.
2.4. Reverse transcription–polymerase chain reaction
Total RNAs were extracted using RNeasy Mini Kit, reverse
transcripted and PCR ampliﬁed using PCR Master Mix and Taq DNA
polymerase from Promega and TSP-1 primers (CTCAGGAC-
CAAAGGCTGCTC; ACTCCTGAATGTGGCAGGTC) and S26 primers
(GTGCGTGCCCAAGGATAAGG; ATGGGCTTTGGTGGAGGTCG). The op-
timal reaction conditions were 30 cycles, 56 °C for TSP-1 and 25
cycles, 50 °C for S26. The resulting PCR products were visualized by
ultraviolet after staining with ethidium bromide.
2.5. Cell transfection
FTC-133 cells were transfected with nontargeting control scRNA
(scRNA-cells) or siRNA speciﬁc to ATF-2 (siRNA-cells) using
Lipofectamine RNAiMAX (Invitrogen), following the manufacturer's
instructions (Santa Cruz Biotechnology).
2.6. Cell viability
About 104 cells/mL were plated in 96-well plates and incubated
until exponential growth phase was reached. Twenty-four hours later,
CPT or DOX (5 μM) were added. At indicated times, 10% (vol./vol.)
UptiBlue (Interchim) was added. Plates were incubated for additional
3 hours and reduction of Uptiblue was then measured spectro-
ﬂuorometrically (λex: 530–560 nm; λem: 590 nm) [5]. Viability data
are presented as percent versus control.
2.7. Detection of apoptosis
After treatment, cells were washed twice with PBS and incubated
for 15 min at 37 °C with 200 μL Hoechst-33258 (20 μg/mL in PBS).
Apoptotic cells characterized by chromatin condensation were
observed under ﬂuorescence microscope (λex: 351.1–363.8 nm; λem:
390–480 nm). Apoptotic cells were scored in three replicate wells for
each treatment. Results are expressed as percentage of total cell
numbers.
2.8. Caspase-3 activity
After incubation, cells were washed twice with PBS and scrapped
with ice-cold lysis buffer as provided by Promega (caspACE assay kit).
Fifty micrograms of cytosolic fraction were incubated with the
caspase-3 colorimetric substrate. Absorbance was measured at
405 nm with a multichannel plate reader (Metertech. inc. Σ960).
2.9. Statistics
Each experiment was performed at least in triplicate on three
separate sets of culture. Data were expressed as mean±SEM. The
statistical signiﬁcance of differences was calculated using Student'stest. p values referring to corresponding control are NS, not signiﬁcant;
**pb0.01, ***pb0.001.
3. Results
Jun N-terminal kinases (JNKs) regulate cell proliferation as well as
apoptosis dependingon the nature of the stimuli and cell type [18,19]. In
order to analyze the role of JNK in CPT- and DOX- induced TSP-1 down-
regulation andapoptosis inhuman thyroid carcinomaFTC-133 cells, CPT
andDOX effectswere ﬁrst examined on JNKphosphorylation. Eachdrug
was used at 5 μM, the concentration that was able to induce 50% of cell
death after 24 hours of treatment (data not shown). As shown in Fig. 1A,
JNK phosphorylation was strongly induced in presence of 5 μM of CPT
andDOXas compared tountreated cells. This suggests that CPT andDOX
up-regulate the JNK pathway.
We previously showed that the pro-apoptotic effects of CPT and DOX
on FTC-133 cells are mediated by de novo ceramide synthesis [6]. We
therefore investigated the impact of this pathway in CPT and DOX-
mediated JNK activation and examined whether C2-ceramide could
mimic CPT and DOX effect. Western blot analysis of JNK phosphorylation
showed thata20 μMdoseofC2-ceramide induced JNKphosphorylation in
a time-dependent manner (Fig. 1A). When FTC-133 cells were treated
with CPT or DOX in the presence or not of Fumonisin B1 (FB1), a chemical
ceramide synthase inhibitor, JNK phosphorylation induced by CPT or DOX
was dramatically inhibited (Fig. 1B). These results thus suggest that a de
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signaling.
To assess whether cell death induced by CPT and DOX required JNK
activation, cells were incubated with CPT or DOX in the presence or
not of 20 nM SP600125, a JNK inhibitor, and cell viability was analyzed
by UptiBlue assay (Fig. 2A). Viable FTC-133 cell number decreased in a
time-dependent manner following incubation with CPT and DOX and
amaximal effect was observed after 12 hours of treatment (45% of cell
death) (Fig. 2A). Chemical JNK inhibition by SP600125 was able to
prevent loss of cell viability induced by CPT and DOX suggesting a
crucial role for JNK. Various SP600125 concentrations were tested and
similar data were obtained using 20 and 40 nM JNK inhibitor afterFig. 3. SP600125 effect on CPT and DOX-induced activation of caspase-3 and apoptosis. FTC-1
20 nM SP600125 for the indicated times. Apoptotic cells were identiﬁed by confocal micros
was detected byWestern blotting (B) and caspase-3 activity wasmeasured by caspACE assay24 hours of incubation (data not shown). Importantly, the loss of cell
viability induced by exogenous C2-ceramide was totally prevented in
cells treated with 20 nM SP600125 (Fig. 2B), thus demonstrating the
involvement JNK pathways in ceramide-induced cell death.
As previously reported [5], CPT and DOX induced loss of cell
viability by triggering apoptosis (Fig. 3A) in a caspase-3-dependent
manner (Fig. 3B and C). One of the characteristic hallmarks of
apoptosis (i.e. chromatin condensation) using Hoechst staining was
not seen in SP600125-treated FTC-133 cells as compared to CPT- or
DOX- (28±3% and 39±2%, respectively) treated cells (Fig. 3A).
Accordingly, the caspase-3 processing induced by DOX or CPT was
strongly inhibited in FTC-133 cells treated with SP600125 as shown33 cells were incubated with either 5 μMCPT or 5 μMDOX in the absence or presence of
copy after Hoechst reagent labeling. Arrows indicate apoptotic cells. (A). Procaspase-3
kit (C) as described in Experimental procedures. β-actin antibody was used as a control.
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activity with the colorimetric DEVD peptide substrate (Fig. 3C).
SP600125 also prevented C2-ceramide-induced cell apoptosis
(Fig. 4A), pro-caspase-3 cleavage (Fig. 4B) and caspase-3 proteolytic
activity (Fig. 4C). Taken together, these results clearly indicate that
CPT- and DOX-induced apoptosis in FTC-133 cells requires ceramide-
dependent JNK activation.
We previously reported that induction of apoptosis by CPT or DOX
in FTC-133 cells was correlated with the down-regulation of TSP-1
expression [5,6]. Our present data led us to investigate whether JNK
pathway could play a pivotal role in CPT and DOX-inhibited
expression of TSP-1. FTC-133 cells were treated with or without CPTFig. 4. SP600125 effect C2-ceramide-induced activation of caspase-3 and apoptosis. FTC-13
SP600125 for 12 hours. Apoptotic cells were identiﬁed by confocal microscopy after Hoech
Western blotting (B) and caspase-3 activity was measured by caspACE assay kit (C) as descor DOX for different times in the presence or not of SP600125 and TSP-
1 expression was determined by RT–PCR and Western blot analysis.
Both drugs signiﬁcantly decreased TSP-1 mRNA expression (Fig. 5A)
correlated at the protein level (Fig. 5B). Of note, JNK inhibition by
SP600125 prevented TSP-1 down-regulation induced by CPT or DOX
in FTC-133 cells, suggesting a key role of JNK in mediating the effects
of both drugs on TSP-1 expression. Because C2-ceramide mimicked
CPT- and DOX-induced TSP-1 down regulation [6], we next assessed
whether SP600125 could impede TSP-1 down-regulation in C2-
ceramide-treated cells. As shown in Fig. 5C and D, SP600125
prevented C2-ceramide effect onTSP-1 mRNA and protein expression
in FTC-133 cells.3 cells were incubated with 20 μM C2-ceramide in the absence or presence of 20 nM
st reagent labeling. Arrows indicate apoptotic cells. (A). Procaspase-3 was detected by
ribed in Experimental procedures. β-actin antibody was used as a control.
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in apoptosis in response to various stresses and inﬂammatory cytokines
[20,21]. To test whether ATF-2 was required for TSP-1 gene modulation
byCPTandDOX,we analyzedATF-2phosphorylation innuclear extracts
obtained fromCPT- and DOX-treated-cells. As shown in Fig. 6A, CPT and
DOX induced ATF-2 phosphorylation in a time-dependent manner and
this effectwasprevented bySP600125 (Fig. 6B). Similar results onATF-2
phosphorylationwere observedwhenFTC-133 cellswere treatedbyC2-
ceramide and SP600125 (Fig. 6B). These results show that CPT- and
DOX-induced ATF-2 phosphorylation is related to JNK activation
through the ceramide pathway. To conﬁrm the involvement of ATF-2
in CPT- and DOX-induced down-regulation of TSP-1, ATF-2 expression
was silenced by RNA interference strategy. Western blot analysis
conﬁrmed thatATF-2 expressionwasdecreased by83% after 48 hours of
incubation with siRNA anti-ATF-2 whereas it remained unchanged in
scrambled siRNA (scRNA)-transfected cells (Fig. 7A). TSP-1 expression
and cell viability were evaluated in transiently transfected FTC-133 cells
treated with CPT, DOX or C2-ceramide. As shown in Fig. 7B, down-
regulation of TSP-1 expression by CPT, DOX or C2-ceramide was
signiﬁcantly abolished in siRNA-cells while no effect was observed in
scRNA-cells. Moreover, ATF-2 silencing protected FTC-133 cells from
CPT, DOX or C2-ceramide-induced cell death (Fig. 7C). Collectively, ourFig. 5. SP600125 effect on CPT, DOX and C2-ceramide-inhibited expression of TSP-1. FTC-1
absence or presence of 20 nM SP600125 for the indicated times. A and C, TSP-1 mRNA expre
was used as a normalizing control. B and D, TSP-1 protein secreted in the culture mediumdata support the hypothesis that ATF-2 is essential for CPT and DOX-
mediated effects in FTC-133 cells.
4. Discussion
TSP-1 can interact with various proteins of the extracellular matrix
such as proteoglycans, integrins, and ﬁbronectin but can also bind to
components of the ﬁbrinolytic system, cathepsin G and elastase [22].
Numerous cell assays attribute a role for TSP-1 in cell proliferation,
apoptosis, angiogenesis, cell adhesionandmotility [1]. ExpressionofTSP-1
is up-regulated in response to various cytokines and growth factors
including platelet-derived growth factor, epidermal growth factor/
transforming growth factor K (EGF/TGFK) but down-regulated in
response to interleukin-1β, tumor necrosis factor K, interleukin-6, and
bFGF [23,24]. According to these controversial observations, it remains
unclear to appreciate the exact role for TSP-1, in particular in tumor
progression.
We previously demonstrated that both camptothecin (CPT) and
doxorubicin (DOX), two cytotoxic drugs used in cancer chemotherapy,
elicit ceramide accumulation in the human thyroid carcinoma FTC-133
cells through a de novo synthesis pathway. Increased level of ceramides
was responsible for drug-induced FTC-133 cell apoptosis and decrease33 cells were incubated with either 5 μM CPT, 5 μM DOX or 20 μM C2-ceramide in the
ssion was evaluated by RT–PCR. The constitutively expressed S26 “housekeeping” gene
was detected by Western blot. β-actin antibody was used as a control.
Fig. 6. A, Effect of CPT, DOX on phosphorylated ATF-2. FTC-133 cells were treated with
either 5 μM CPT or 5 μM DOX in the absence or presence of 20 nM SP600125 for the
indicated times. B, SP600125 effect on CPT, DOX and C2-ceramide-induced ATF-2
phosphorylation. FTC-133 cells were treated with either 5 μM CPT, 5 μM DOX or 20 μM
C2-ceramide in the absence or presence of 20 nM SP600125 for 8 hours. The nuclear
extracts containing equal amounts of total proteins were resolved by SDS–PAGE and
analyzed by Western blot using anti-phosphorylated ATF-2 as described in Experi-
mental procedures. β-actin was analyzed by Western blot in whole cell extract and
used as a control.
Fig. 7. Role of ATF-2 on CPT, DOX and C2-ceramide-inhibited TSP-1 expression and cell
viability. FTC-133 cells were transfected with nontargeting control scRNA or siRNA-
ATF-2 and treated with either 5 μM CPT, 5 μM DOX or 20 μM C2-ceramide for 24 hours.
ATF-2 expression was evaluated by Western blot using anti-phosphorylated ATF-2
(A). TSP-1 protein secreted in the culture medium was detected by Western blot (B).
Cell viability was determined by Upti-blue assay as described in Experimental
procedures (C). β-actin antibody was used as a control. Results are expressed as
percent of control and represent means±standard deviations (S.D.) of at least three
independent experiments.
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elevation of intracellular ceramide amounts markedly activated the JNK
cascade in primary cultures of bovine endothelial cells and in U937
monoblastic leukemia cells [25]. JNK and p38 kinases are multifunc-
tional signaling networks that inﬂuence cell proliferation, differentia-
tion, apoptosis and responses to stress playing a pivotal role in the signal
transduction from different stimuli [26].
Herein, we demonstrated that the JNK pathway plays a central role in
CPT- and DOX-induced caspase-3 activation and apoptosis in FTC-133
cell. Moreover, CPT and DOX induced JNK phosphorylation through de
novo ceramide synthesis and chemical inhibition of either ceramide
production or JNK activation prevent CPT and DOX effects on TSP-1
expression and cell apoptosis. Other reports have also clearly established
the role of JNK in X-ray, DOX and TRAIL-induced apoptosis in U937 cells,
rat hepatoma cell line, mouse lymphocytic leukemia cells and squamous
cell carcinoma, respectively [27–30]. The primary evidence that JNK
activation could be correlated with apoptosis came from the initial
studies using embryonic ﬁbroblasts derived from JNKs−/− mice [31].
These JNKs−/− mouse embryonic ﬁbroblasts showed resistance to
apoptosis in response to UV irradiation. Moreover, JNK inhibition
abrogated estradiol-induced suppression of TSP-1 synthesis in endo-
thelial cells [32]. The role of JNK signaling in apoptosis is highly
controversial since JNK is activated during cell proliferation as well as
apoptosis [33]. In fact, JNK inhibition markedly suppressed anaplastic
thyroid cancer growth in a reversible cytostatic manner. The combina-
tion treatment with JNK inhibitor plus ionizing radiation induced a
signiﬁcant decrease in clonogenic survival of irradiated cells as
compared with either singular treatment [34]. This is consistent with
previous studies demonstrating that JNK activation is required for DNA
repair and cell survival after treatment with cisplatin in various types of
human cancer cell lines including glioblastoma, ovarian, breast, and
prostate cancer cells [35–37]. Consequently, it has been postulated that
JNK roles during apoptosis depend on cell type, nature of the apoptotic
stimuli, duration of its activation and contribution of downstream
signalingpathways [38]. It appears that sustained JNKactivation is rather
associated with apoptosis whereas acute and transient activation are
involved in proliferative or survival pathways [39,40].Besides the kinase JNK, the p38 MAP kinase was generally
identiﬁed as another kinase able to mediate cell death [41,42].
However, while this assumption is correct in most cases, cause–effect
studies have also reported that p38 activation by stress stimuli may
not necessarily promote death as it can enhance cell survival [43]. In
presence of DOX, CPT or C2-ceramide, the p38 MAP kinase was not
activated in FTC-133 cells suggesting a p38 independent-apoptotic
mechanism (data not shown). In normal pig thyroid cells, generation
of cAMP promotes survival and prevents apoptosis induced by diverse
stimuli [44]. In this cell model, we previously demonstrated that
increased level of endogenous ceramide contributed to the apoptotic
process by preventing survival pathways. Moreover, ceramides
inhibited adenylyl cyclase activity and down-regulated ERK1/2 but
did not affect p38 and JNK phosphorylation [45].
JNK phosphorylates the transcription factors c-Jun, ATF-2, Elk-1,
p53, and c-Myc, as well as anti-apoptotic Bcl2 family members [19].
These transcription factors play a key role in the control of cell
proliferation, cell cycle progression and apoptosis [46–50]. It has been
proposed that JNK-induced ATF-2 phosphorylation might control
apoptosis in response to stresses such as UV light, osmotic stress,
hypoxia and inﬂammatory cytokines [51,52]. Therefore, we evaluated
ATF-2 phosphorylation in response to CPT, DOX and C2-ceramide
treatment and our data demonstrated that ATF-2 was phosphorylated
in response to these agents. This phosphorylation was inhibited by
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keeping with results that showed that JNK was rapidly activated in
nicotine-treated cells preceding ATF-2 phosphorylation [53]. ATF-2 is
one member of the ATF/cAMP-response element-binding protein
family and is characterized by a basic zipper domain that acts as a
DNA-binding region. It regulates gene expression via its binding to the
recognition sequences of the cAMP-response element (CRE) or via
formation of an heterodimer with AP-1 (activation protein-1) that
binds to CRE sequences [54]. Because we reported that ATF-2 was
phosphorylated by its upstream activator JNK, we sought to
determine its role in the down-regulation of TSP-1 and induction of
apoptosis in CPT-, DOX- and C2-ceramide-treated cells. Our results
revealed that ATF-2 silencing abolished CPT and DOX effects by down-
regulation of TSP-1 and induction of apoptosis. Other reports have
also demonstrated that JNK activation precedes programmed cell
death induced by hypoxia. Moreover, JNK inhibition led to a decrease
of active caspase-3 and ATF-2 phosphorylation which correlated with
a decrease in the number of apoptotic cells [55]. In summary, our data
put in evidence that JNK/ATF-2 is activated by both CPT and DOX via
de novo ceramide leading to TSP-1 down-regulation and consequently
apoptosis in FTC-133 cell.
Our previous studies demonstrated that CPT- and DOX-down
regulated TSP-1 is correlated to induction of apoptosis in FTC-113 cells
[5,6]. In parallel, the invasive potential of FTC-238 (derived from a
lung metastasis FTC-133 cells) was also inhibited by antibodies
against TSP-1 [56]. These ﬁndings support the hypothesis that the
levels of TSP-1 could directly drive the thyroid cancer resistance to
doxorubicin treatment, thus impairing the efﬁciency of such chemo-
therapy in clinical practice.
The treatment of most patients with thyroid carcinoma is based on
surgery, radioactive iodine, and thyroid hormone therapy [57].
Cytotoxic systemic chemotherapies for advanced, metastatic thyroid
carcinomas have limited effectiveness. During the past decade,
biologic discoveries have sparked clinical trials using novel, targeted
therapies for advanced thyroid carcinomas. Our present data
demonstrate that pharmacological activation of JNK/ATF-2 may
contribute to the attenuation of TSP-1 anti-apoptotic effect by
inhibition of its expression. Thus, the JNK/ATF-2 signaling pathway
may be studied further as a critical target for a novel approach to
overcome chemoresistance in thyroid carcinoma.
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